Biotech News
MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
investors.medicinova.com2026-05-06 15:07 EST
LA JOLLA, Calif. , Nov. 04, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc. , a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the completion of patient enrollment in its Phase 2 clinical